Top Tech Companies (1,916)
Don't see your company?
Create a company profile
InQ Biosciences provides integrated cell growth and cell analysis systems for research and development in the cell and tissue growth sector.
Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY® System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics and clinical research. Our mission is to equip genomic and clinical testing laboratories with practical solutions that increase productivity and decrease time to results. Whether assessing sample quality, screening samples for actionable mutations, or enabling routine genetic testing for tens to thousands of samples, our products and services help laboratories translate genomic discoveries into mainstream clinical practice. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. Our founding physicians entered the molecular diagnostics market focused on the most common pathogens that impact the population – making products that were cost-effective, reduced waste, and easy to use. Our mission is to empower providers and researchers with the molecular insights needed to deliver exceptional patient care. We do this by developing, producing, and supplying multiplex assays for research use. We believe we can make the world a healthier place by improving the delivery and use of molecular technologies. As a physician-founded company, we’re passionate about helping people, sharing our expertise, and improving healthcare outcomes. It is a privilege to do the work we do – and we have built an exceptional reputation as problem-solvers with an unwavering commitment to integrity. With locations in Alabama and California, and remote workers nationwide, we continue to seek top talent to support our growth, develop new molecular diagnostics, and better serve our customers. Our suite of employee benefits includes medical, dental, and vision insurance. And our 401K plan with company match program, paid time off, extensive voluntary benefits, and staff appreciation programs make Molecular Designs an employee-first organization.
At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at scale. Taken together, our platform unlocks the ability to search biology, where complex questions about human disease can be asked and answered for the first time. We build and provide these capabilities to our network of leading academic institutions and pharmaceutical companies around the world. Our collaborative research spans numerous indications, with a core focus on unmet needs in oncology and autoimmune diseases. We advance science by accelerating data generation, methods development, research insights, and high-impact publications. Our interdisciplinary team of scientists, engineers, researchers, and investors focuses on decoding biological systems to make drug discovery, development, and patient care more deterministic. Come join us on our mission to decipher biology and meaningfully improve the way patients are treated.
Arima Genomics provides unparalleled access to the spatial and temporal changes in the 3D structure of the genome that alters gene regulation and cellular function. #3DGenomics
Tansna Therapeutics is a developer of an oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy.
Lucid Scientific is a biotechnology company that designs and develops a series of real-time cellular activity monitors.
DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
RS BioTherapeutic’s first investigational compound (RSBT-001) is a semi-synthetic, nebulized, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. Our premise is that RSBT1 provides therapeutic benefit through modulation of the Interleukin response to inflammation and modulation of alveolar macrophages responsible for fibrotic changes within the lungs. RSBT-001 is unique in that it is a polar adaptive molecule exhibiting both hydrophilic and lipophilic properties, which leads to high absorption and bioavailability enhancing therapeutic benefit.
Blink Science is a biotechnology company that makes handheld, low-cost point-of-care diagnostic testing available across the globe.
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Accentia Biopharmaceuticals discovers, develops and commercializes immunotherapies to treat autoimmune-related diseases and cancer.
Summit Biosciences is developing, manufacturing & commercializing generic and innovative nasal spray drug products.
G-CON Manufacturing, Inc.’s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space. Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON’s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON’s initial and more recent innovations. At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
BioConsortia, Inc. is developing highly effective microbial solutions that enhance plant phenotypes and increase crop yields. We are pioneering the use of directed selection in identifying teams of microbes - working like plant breeders and selecting plants based on targeted characteristics, then isolating the associated microbial community. Our proprietary Advanced Microbial Selection (AMS) process enriches the crop microbiome, allowing us to identify microbes that influence the expression of beneficial traits in plants. We are currently focused on products for fertilizer use efficiency, growth improvement and abiotic tolerance, with plans to invest in biocontrol and metabolite expression with the right partner. www.bioconsortia.com
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
Helaina is a biotech company pushing the boundaries of what food can do for health.
Ensign-Bickford Industries, Inc. (EBI), founded in 1836, is a privately-owned high technology conglomerate focused in space & defense, pet food science, and biotechnology. We participate in businesses that are relevant to the future of the world and have multigenerational growth prospects. EBI companies are unified by a common shared operating system and a common set of values.
